Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood. 2022 Dec 1;140(22):2407-2411. doi: 10.1182/blood.2022016567.

Sun Loo^{1

2

3}, Richard Dillon^{4

5}, Adam Ivey⁶, Natasha S Anstee^{1

3}, Jad Othman^{4

5}, Ing Soo Tiong^{3

7}, Nicola Potter⁵, Jelena Jovanovic⁵, Manohursingh Runglall⁵, Chyn Chua Chong^{1

3}, Ashish Bajel², David Ritchie², Kelli Gray², Zhi Han Yeoh², Michelle McBean⁷, Amanda Gilkes⁸, Ian Thomas⁹, Sean Johnson⁹, Nigel H Russell⁴, Andrew H Wei^{1

2

3}

¹ The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
² Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.
³ Department of Haematology, The Alfred Hospital, Melbourne, Australia.
⁴ Guy's and St Thomas Hospital, London, United Kingdom.
⁵ Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
⁶ Department of Pathology, The Alfred Hospital, Melbourne, Australia.
⁷ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁸ Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom.
⁹ Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.

No abstract available

Publication types